Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other liabilities | 29 | 5 |
| Net cash used in operating activities | (86,883) | (66,511) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (449) | (547) |
| Purchases of marketable securities | (133,839) | — |
| Maturities and sales of marketable securities | 97,831 | 69,926 |
| Net cash (used in) provided by investing activities | (36,457) | 69,379 |
| Cash flows from financing activities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s capex?
- Cogent Biosciences, Inc. (COGT) reported capex of $449K in Q1 2026.
- How has Cogent Biosciences, Inc.'s capex changed year-over-year?
- Cogent Biosciences, Inc.'s capex decreased by 17.9% year-over-year, from $547K to $449K.
- What is the long-term trend for Cogent Biosciences, Inc.'s capex?
- Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s capex has grown at a -39.0% compound annual growth rate (CAGR), from $6.86M to $1.55M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Cogent Biosciences, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude